Thread by @chamath

1/ As a parent, I often wonder whether there is a way for technology to be part of the solution to our country’s growing concerns around mental health.

And then we met @EddieMartucci and his team at @AkiliLabs. $DNAA $AKLI
bloomberg.com/news/articles/…

2/ @AkiliLabs is creating a new class of medicine. Their first product is a first-of-its-kind FDA-cleared prescription video game to treat pediatric ADHD in 8-12 year-olds.

3/ Their technology targets the fronto-parietal attention control networks of the brain to improve attention function (e.g., focus, multitasking).

4/ Akili's lead product – EndeavorRx – has been clinically validated and shown similar outcomes to prescription drugs. This breakthrough therapy is powered by technology that directly targets cognitive function vs. current treatments which focus on symptoms and coping strategies.

5/ Importantly, while Akili's patented technology is used to treat ADHD today, they have the opportunity to eventually treat a whole host of other cognitive issues like major depressive disorder, multiple sclerosis, and autism spectrum disorder.

6/ We’re excited our biotech SPAC platform is able to partner with another company that is rethinking how we approach some of America’s most pressing healthcare issues, in this case our cognitive health.

Read more in our investment thesis. Disclaimer: bit.ly/dnaa-info